Yunkang Group Ltd (2325) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Yunkang Group Ltd HK$1.24, price HK$0.46, upside +169.6%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Yunkang Group Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China.
Show more
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests; and genetic reproduction and screening tests. In addition, the company offers routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases. Further, it provides technology platforms, including AI + healthcare; high-throughput sequencing technology platform; PCR technology platform; digital pathology remote diagnosis platform; and other technology platforms. The company provides its services through independent clinical laboratories and on-site diagnostic centers. Yunkang Group Limited was founded in 2008 and is headquartered in Guangzhou, the People's Republic of China.
Stock analysis
Yunkang Group Ltd (2325) currently trades at HK$0.4600, while our model-based Fair Value estimate is HK$1.24, implying the stock looks roughly 62.9% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$6.09 per share, and 16 of the 23 models we run sit above the HK$0.4600 price.
Bear case: the Multiples group reads lowest at HK$0.1300, and 7 of the 23 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Yunkang Group Ltd reported revenue of 601M CNY in FY2025 versus 1.7B CNY in FY2021, a compound −22.8%/yr. Reported net income was 2.9M CNY in FY2025, compounding −70.4%/yr from FY2021.
Key figures
Market cap HK$398M (≈ $50.7M) · P/E ratio 68.0 · P/S ratio 0.33 · EPS (TTM) HK$−0.0900 · Dividend yield 2.8% · Net margin 0.5% · Return on equity 0.3% · Return on assets (EBIT) 0.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 67% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 170%, 2325 screens cheaper than that median.
Fair Value models
Bear HK$1.24Fair Value HK$1.24Bull HK$1.24
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−15.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−45.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.9%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−57.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−60.5%
Dividend (yield on the price)2.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.28% → 6%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 138 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside+169.6% · Top 25%
Profitability
Return on equity (TTM)0.3% · Below median
Return on assets1.9% · Above median
Net margin (TTM)0.5% · Below median
Operating margin (TTM)31.7% · Top 25%
Growth and dividend
Revenue growth−13.2% · Bottom 25%
Dividend yield (TTM)2.8% · Above median
Balance sheet
Debt / equity0.15× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Yunkang Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2325
Frequently asked questions
Is Yunkang Group Ltd (2325) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$1.24 versus a price of HK$0.4600, about +170% upside (undervalued).
What is the fair value of 2325?
Our model-based fair value for Yunkang Group Ltd is HK$1.24 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$0.4600.
What is the quality score of 2325?
Yunkang Group Ltd has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Yunkang Group Ltd (2325)?
Our model-based price target is the fair value of HK$1.24 (as of Sep 27, 2026) from 23 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Yunkang Group Ltd stock forecast for 2026?
Our models put fair value at HK$1.24, about +170% upside versus a price of HK$0.4600 (undervalued). The calculation is refreshed regularly with new filings.
What is the revenue of Yunkang Group Ltd (2325)?
Yunkang Group Ltd reported trailing-twelve-month revenue of about HK$601M (latest available figure, as of Sep 27, 2026).
Does Yunkang Group Ltd pay a dividend?
Yunkang Group Ltd currently shows a dividend yield of about 2.75% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of Yunkang Group Ltd (2325)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Yunkang Group Ltd it is HK$1.24 per share (as of Sep 27, 2026), against a price of HK$0.4600. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Yunkang Group Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2325 trades below its calculated fair value: price HK$0.4600, fair value HK$1.24, a gap of about +170% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2325?
No. The price is what the market pays today (HK$0.4600); the fair value is what the company's own numbers justify (HK$1.24). For Yunkang Group Ltd the two are HK$0.7800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Yunkang Group Ltd worth?
The market values Yunkang Group Ltd at about HK$398M (market capitalisation, as of Sep 27, 2026). Per share that is HK$0.4600; our models calculate a fair value of HK$1.24 per share.
What is the P/E ratio of 2325?
Yunkang Group Ltd trades at a price-to-earnings ratio of 68.0 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$1.24 is built from several models across several years. Other multiples: P/B 0.3, P/S 0.7.
How solid is the balance sheet of Yunkang Group Ltd (2325)?
Balance-sheet figures for Yunkang Group Ltd (as of Sep 27, 2026): return on equity 0.3%, debt of 0.15 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is 2325 from its 52-week high?
Yunkang Group Ltd trades at HK$0.4600, about 67% below its 52-week high of HK$1.40 and 3% above the low of HK$0.4450 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.24 is for.
Which stocks are comparable to Yunkang Group Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Yunkang Group Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price HK$0.4600, calculated fair value HK$1.24 (+170%), Quality Score 66/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2325 calculated?
We run Yunkang Group Ltd through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.24, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Yunkang Group Ltd currently trades 63 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Yunkang Group Ltd (2325)?
The closing price on Sep 30, 2026 was HK$0.4600. Our model-based fair value is HK$1.24, about +170% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Yunkang Group Ltd right now?
The price is below even our cautious bear case (HK$1.24). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Yunkang Group Ltd
How large is the market capitalisation of Yunkang Group Ltd (2325)?
The market capitalisation of Yunkang Group Ltd is HK$398M (≈ $50.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Yunkang Group Ltd (2325)?
The price-to-sales ratio of Yunkang Group Ltd is 0.33 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Yunkang Group Ltd (2325)?
Earnings per share at Yunkang Group Ltd are HK$−0.0900 (price ÷ EPS = P/E 68.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Yunkang Group Ltd (2325)?
The dividend yield of Yunkang Group Ltd is 2.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Yunkang Group Ltd (2325)?
The net margin of Yunkang Group Ltd is 0.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Yunkang Group Ltd (2325)?
The return on equity (ROE) of Yunkang Group Ltd is 0.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Yunkang Group Ltd (2325)?
On an EBIT basis the return on assets of Yunkang Group Ltd is 0.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Yunkang Group Ltd (2325)?
The operating margin of Yunkang Group Ltd is 31.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Yunkang Group Ltd (2325)?
Revenue at Yunkang Group Ltd is growing −13.2% versus a year earlier (3y avg −45.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Yunkang Group Ltd (2325)?
Earnings per share at Yunkang Group Ltd are growing −82.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Yunkang Group Ltd (2325) generate?
The free cash flow of Yunkang Group Ltd is HK$246M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Yunkang Group Ltd (2325) hold?
Yunkang Group Ltd holds more cash than debt, HK$894M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Yunkang Group Ltd in the live analysis
One click puts Yunkang Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
